Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 8/20 | 0.82 |
| ▸ | NR1I2 | O75469 | 6/20 | 0.67 |
| ▸ | TAS2R8 | Q9NYW2 | 2/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.38 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.37 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8151071 | 0.90 | CACNA1B (1.00) | CACNA1BNR1I2TAS2R8 | |
| SCHEMBL8156765 | 0.87 | CACNA1B (0.75) | CACNA1BNR1I2TAS2R8 | |
| SCHEMBL8158186 | 0.84 | CACNA1B (0.58) | CACNA1BNR1I2TAS2R8PTGDR2DGAT2 | |
| SCHEMBL8144010 | 0.82 | CACNA1B (0.57) | CACNA1BNR1I2TAS2R8PTGDR2DGAT2 | |
| SCHEMBL8157382 | 0.82 | CACNA1B (0.70) | CACNA1BNR1I2TAS2R8 | |
| SCHEMBL8152439 | 0.81 | NR1I2 (1.00) | CACNA1BNR1I2 | |
| SCHEMBL8156762 | 0.81 | NR1I2 (0.78) | CACNA1BNR1I2 | |
| SCHEMBL8156757 | 0.80 | NR1I2 (0.83) | CACNA1BNR1I2 | |
| SCHEMBL8158178 | 0.79 | NR1I2 (0.75) | CACNA1BNR1I2 | |
| SCHEMBL8156333 | 0.79 | NR1I2 (0.75) | CACNA1BNR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100087446-A1 | 2-SUBSTITUTED INDOLE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | MERCK SHARP & DOHME CORP. | 2010-04-08 | — | — | US | disclosed |
| US-20100087446-A1 | 2-SUBSTITUTED INDOLE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | MERCK SHARP & DOHME CORP. | 2010-04-08 | — | — | US | disclosed |
| WO-2008133867-A1 | 2-SUBSTITUTED INDOLE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | MERCK & CO., INC. (US) | 2008-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087446-A1 | 2-SUBSTITUTED INDOLE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | TRPV1, CACNA1S, TRPV2 | CACNA1B 13/4885NR1I2 1761/4885TAS2R8 1156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.